Abstract Details

Title Sleep-Wake Intracerebral Fluid Tracking (SWIFT) using Continuous Wave Functional Near- Infrared Spectroscopy (CW fNIRS): A Novel Approach to Visualizing TBI-Associated Neurodegeneration

Topic Sleep

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 468

Objective

To design a wearable device capable of tracking glymphatic fluid flow during sleep in order to correlate changes in glymphatic flow with changes in the sleep cycle in warfighters with and without a history of TBI.

Background Sleep disorders are diagnosed in over fifty percent of military traumatic brain injury (TBI) patients, and the incidence of dementia and other neurodegenerative diseases among TBI patients is increased compared to the general population. One possible mechanism by which TBI propagates neurodegeneration is via sleep disruption causing reduced glymphatic clearance of toxic byproducts of neural activity such as amyloid and tau. To examine this, we propose a novel approach using Continuous Wave Functional Near-Infrared Spectroscopy (CW fNIRS). CW fNIRS can be used to assess interstitial fluid flow at the surface of the brain by tracking changes in absorption over time and examining very-low-frequency systemic changes benchmarked to sleep stages tracked with traditional polysomnographic techniques.

Design/Methods We co-developed a novel wearable CW fNIRS device with supporting software and integrated Bluetooth connectivity capable of continuous neuroimaging during sleep. Benchtop testing in a 50% water/50% cream interface was performed in order to validate our device’s performance relative to commercially-available fNIRS devices.

Results We successfully developed a functional CW fNIRS device with two source emitters (850nm, 980nm) to track fluid oscillations in the water/cream interface. To improve noise rejection, the data was sampled at a high rate and then filtered and decimated to arrive at the output sample rate (80Hz). Preliminary testing results indicate that our novel CW fNIRS device performs equivalent to commercially-available fNIRS devices.

Conclusions While product testing is ongoing, preliminary comparative device benchmarks suggest the successful development of a portable, Bluetooth CW fNIRS headband capable of measuring fluid dynamics in the neural cortex during sleep. Subsequent clinical trials are pending IRB approval.

Authors/Disclosures
PRESENTER	No disclosure on file
J. Kent Werner, Jr., MD, PhD (Uniformed Services University)	Dr. Werner has received personal compensation for serving as an employee of Cogentis Therapeutics. Dr. Werner has stock in Cogentis Therapeutics. Dr. Werner has received intellectual property interests from a discovery or technology relating to health care. Dr. Werner has received intellectual property interests from a discovery or technology relating to health care. Dr. Werner has received personal compensation in the range of $100,000-$499,999 for serving as a Neurologist with United States Navy. Dr. Werner has received personal compensation in the range of $50,000-$99,999 for serving as a CEO / CoFounder with Cogentis Therapeutics.
Matthew C. Miller	Mr. Miller has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Franck G. Amyot, PhD (HJF)	Dr. Amyot has nothing to disclose.
Kimbra L. Kenney, MD, FAAN	Dr. Kenney has nothing to disclose.
J. Kent Werner, Jr., MD, PhD (Uniformed Services University)	Dr. Werner has received personal compensation for serving as an employee of Cogentis Therapeutics. Dr. Werner has stock in Cogentis Therapeutics. Dr. Werner has received intellectual property interests from a discovery or technology relating to health care. Dr. Werner has received intellectual property interests from a discovery or technology relating to health care. Dr. Werner has received personal compensation in the range of $100,000-$499,999 for serving as a Neurologist with United States Navy. Dr. Werner has received personal compensation in the range of $50,000-$99,999 for serving as a CEO / CoFounder with Cogentis Therapeutics.

��ɫ��

��ɫ��